Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women.

In conjunction with more prospective collaboration, plans are evolving to ensure that we will be better prepared to address similar situations especially in paediatrics and pregnant women where experience is limited and actual practice relies heavily on leveraging data from other populations and indications.